<DOC>
	<DOCNO>NCT01342939</DOCNO>
	<brief_summary>The purpose study describe incretin effect postprandial incretin response patient MODY2 MODY3 group match healthy subject . In sulphonyl urea treat subject purpose also compare incretin effect without treatment . In healthy subject purpose also investigate incretin effect increase level endogen incretin hormone .</brief_summary>
	<brief_title>Pathophysiological Implications Incretin Hormones Maturity Onset Diabetes Young ( MODY )</brief_title>
	<detailed_description>Comparison insulin secretion ( AUC ) experimental day . Furthermore comparison GIP , GLP1 glucagon response well plasma glucose level .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Caucasians 18 year BMI &gt; 19 kg/m2 Negative pancreatic beta cell glutamate decarboxylase65 ( GAD65 ) autoantibodies Normal haemoglobin Normal bloodpressure Informed concent Known liver disease affect liver enzymes ( ALAT/ASAT &gt; 2 x upper normal limit ) Nephropathy ( see creatinine &gt; 130 Î¼M / albuminuria ) Treatment medication discontinue 12 hour Any condition investigator feel would interfere trial participation Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Monogenetic diabetes</keyword>
	<keyword>Diabetes mellitus</keyword>
</DOC>